TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Patient & Caregiver Mood - Anxiety as Measured on the Hospital Anxiety and Depression Scale (HADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient & Caregiver Mood - Depression as Measured on the Hospital Anxiety and Depression Scale (HADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in fat oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Exhaled Nitric Oxide (FENO) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protease levels in chronic wounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with or without polymorphism in genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Natural History of Osteogenesis Imperfecta (OI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-reported change in shoulder functional outcome OSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of shoulder stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-tau, Steady State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Total Oral Clearance, Single Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in SGRQ Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Re-excision rate for close or positive margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: implementation rates for early mobility
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pharmacokinetics characteristics of levobupivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pelvic recurrence-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Intracranial Pressure Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patency of ventricular catheters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change of WOMAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of KOOS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced a Serious Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Achieved Sustained Viral Response 24 Weeks After the End of Treatment (SVR24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cesarean scar thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change From Baseline in the Area of Geographic Atrophy (GA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Ocular or Non-ocular Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Ocular or Non-ocular Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incident Gender-Based Violence (GBV)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical/radiographic complete rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Genetic imbalances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standardized uptake value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum serum concentration (Cmax) of THC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach maximum serum concentration (Tmax) of THC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC 0-24 h) of THC in serum concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the dynamic standing balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Burn Specific Pain Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual Analogue Scale for anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CIPN symptomology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement in detecting fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Oxford Utilitarianism Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: aerobic fitness test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue impact scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: 1-year Pregnancy Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: 3-year Pregnancy Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Safety of low-dose suramin
Endpoint domain: Adverse events/effects
Primary endpoint: Score of Urinary Symptom Profile (USP) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of HPV types
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Generalized Anxiety Disorder 7-item Scale (GAD-7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intervention free survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of subjects with severe infections
Endpoint domain: Adverse events/effects
Primary endpoint: Change in UAS7 (urticaria activity score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oswestry Disability Index (ODI) at 2 years compared to preoperative ODI
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diagnosis or rule-out of acute coronary syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maintenance of HIV risk-free drug behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cognitive impairment prevalence
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Presence of clear signs of contact extension
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Emotional Impact of Cancer Treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of women receiving birth induction after week 41
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Insulin dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Ductus diameter mm/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative dosage of morphine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduced Depression Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Levels of Insulin Like Growth Factor-1 (IGF-I)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Chemotherapy Associated Anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: In-stent stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Early Developmental characteristics of children with DCD during pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Early Developmental characteristics of children with DCD during toddlerhood
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Early Developmental characteristics of children with DCD during preschooler stage
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Neuropsychological phenotype assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Methylation of cpg sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Copenhagen score modified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjects With Safety Related Events or Findings
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients who get a BMD
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of patients started on active osteoporosis therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Serum glucose measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent change in global left ventricular ejection fraction (LVEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Obsessive Compulsive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in house dust mite allergen concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: EOS measurement of intrinsic reserve extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EOS measurement of extrinsic extension reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EOS measurement of global extension reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in left ventricular end-diastolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Any Adverse Event Leading to Permanent Discontinuation of Study Drug
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with metabolic non-response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Progression free proportion
Endpoint domain: Mortality/survival
Primary endpoint: Number of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of Postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Linear running sprint time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ergonomic risks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of CBT-1®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Donor Site Wound Closure
Endpoint domain: Adverse events/effects
Primary endpoint: Discouragement of smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in concentration of C-peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in metabolomic response to a test meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cartilage turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between cbNIPT and CVS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: 12-month overall survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Achieving Prostate-specific Antigen (PSA) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants Achieving Complete Response (CR) or Partial Response (CR) to Protocol Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in retention
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Short-term Relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Use of aftercare services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Disease control (CR, PR, SD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in self-reported smoking status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of adverse events of procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Number of adverse events within 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of older ED patients receiving potentially inappropriate medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feeding-tube-free food intake (days)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantity of Lactobacillus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alpha diversity of microbes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shannon index (Beta diversity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Occurrence of Kidney Disease Progression
Endpoint domain: Mortality/survival
Primary endpoint: Change in [11C]carfentanil binding in brain in response to feeding prior to weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in [11C]carfentanil binding in brain in response to feeding post weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: FACIT-Fatigue Subscale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: mean of temporomandibular joint disc thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean of temporal muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean of masseter muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean of masseter muscle width
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean of masseter muscle cross-sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean of sternocleidomastoid muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: combined rate of failure at the end of treatment and relapse by 30 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of serious adverse events at any time during chemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Immediate Procedural Technical Success
Endpoint domain: Adverse events/effects
Primary endpoint: Absence of Major Adverse Events (MAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Aneurysm rupture
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of metachronous gastric neoplasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Back-specific function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety and tolerability of AZD2551
Endpoint domain: Adverse events/effects
Primary endpoint: Concentration of AZD2551 in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: area under the plasma concentration time curve (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HEI-2015 Total and Component Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hierarchical composite of death, heart transplant or left ventricular assist device (LVAD) implantation, HF hospitalizations, worsening HF events treated as an outpatient, and change in Kansas City Cardiomyopathy Questionnaire (KCCQ)
Endpoint domain: Mortality/survival
Primary endpoint: Change in affect-biased attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: daily combined scores of medication and rhinoconjunctivitis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake of [18F]-IMAFIB expressed as standardised uptake value (SUV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hyperbilirubinemia levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Brain Glucose Metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of estimated glomerular filtration (eGFR) decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fraction of patients that become MRD-negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in impulsive eating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Accuracy of landmark epidural level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Persistent Negative Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Mini-mental State Examination (MMSE) Total
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Neuropsychiatric Inventory (NPI) Score of Psychiatric Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dentine hypersensitivity relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correction of acetabular fragment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Chest Xray radiographic results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of cytokines released from PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in clinician-assessed PTSD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MAP changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HR changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time at Which Cmax Was Observed (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half Life of Terminal Elimination Phase (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject's weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of subjects who self-report weight to the clinic
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Severity of Dry Eye Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of change in bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Speech in Noise Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Auditory Brainstem Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spatial Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NPRS-11
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Boston bowel preparation quality scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: ECP concentrations in supernatants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Falls recorded in the Electronic Medical Record
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants on Tocilizumab Treatment at Month 6
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Measured Adherence to Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Quadriceps Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Respiratory Distress Severity Score (RDSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: postinfectious IBS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: modified Rankin scale (mRs) at 90 days
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Success rate of inferior alveolar nerve block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of pelvic static disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Disease response/composite response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FFbH-R
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of Major Adverse Events (MAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Biochemical Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of linezolid in blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pharmacokinetics of linezolid in urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes